I-Nuvaxovid kunye ne-Covovax: ugonyo lwe-10 kunye neye-9 lwe-COVID-19 kuLuhlu lokuSebenzisa oluNgxamisekileyo lwe-WHO

Ukulandela uvavanyo kunye nokuvunywa kwe-Arhente ye-European Medicines Agency (EMA), i-WHO ikhuphe uluhlu lokusetyenziswa olungxamisekileyo (EUL) lwe-Nuvaxovid ngomhla we-21 Disemba 2021. Ngaphambili kwi-17 kaDisemba 2021, WHO ikhuphe uluhlu losetyenziso olungxamisekileyo (EUL) lweCovovax.  

I-Covovax kunye ne-Nuvaxoid ke ngoko yaba yi-9^th Kunye ne10^th Covid-19 zokugonya kuluhlu losetyenziso olungxamisekileyo lwe-WHO.  

Zombini iNuvaxovid kunye neCovovax zokugonya Iprotheyini encinci zokugonya, kwaye usebenzise i-nanoparticles. Ezi zenziwa kusetyenziswa itekhnoloji ye-nanoparticle ephinda iphinda isebenze ukuvelisa i-antigen ephuma kwiprotein ye-coronavirus spike (S) kwaye iqulethe i-saponin-based Matrix-M adjuvant enelungelo elilodwa lomenzi wechiza ukunyusa impendulo yomzimba yokuzikhusela kunye nokuvuselela amanqanaba aphezulu e-anti-antibodies.  

Ezi zimbini zokugonya ziqulethe iprotein ye-antigen ecocekileyo engakwaziyo ukuphindaphinda, kwaye enokubangela isifo se-COVID-19.  

I-Nuvaxovid & Covovax ifuna iidosi ezimbini kwaye izinzile kwi-2 ukuya kwi-8 °C yobushushu obufakwe efrijini. 

INuvaxovid yaphuhliswa nguNovavax, Inc., inkampani yaseMelika yebhayoloji esekwe eMaryland. Yeyona mveliso yokuqala yeCovovax.    

I-Covovax yaphuhliswa nguNovavax kunye ne-Coalition for Epidemic Preparedness Innovations (CEPI) kwaye iveliswe yiSerum Institute of India (SII) phantsi kwelayisensi evela eNovavax. Le yinxalenye yepotfoliyo yeziko le-COVAX, inika unyuso olufuneka kakhulu kwiinzame eziqhubekayo zokugonya abantu abaninzi kwiindawo ezinqongopheleyo zezibonelelo.  

I-Covovax kunye ne-Nuvaxoid ziyafana ne-Cuba's Soberana 02 kunye ne-Abdala ekugonyeni okusekwe kwiprotheyini ngokuchasene ne-COVID-19 kodwa iCuba's. zokugonya sebenzisa ngokuthe ngqo i-RBD (isizinda sokubopha i-receptor) kwiprotein ye-spike, enoxanduva lokungena kwentsholongwane kwiiseli zomntu ngelixa i-Nuvaxovid kunye ne-Covovax ijolise kwi-coronavirus spike (S) protein.  

NjengaseCuba zokugonya, I-Nuvaxovid & Covovax nayo inenzuzo yokuzinza kwi-2-8 ° C kwaye ingalungiselelwa ngokulula ukwenza izitofu ezintsha zokugonya kwiintlobo ezitshintshileyo.  

Le proteni ikhankanywe ngasentla esekwe kwi-COVID-19 zokugonya yohluke ngokuphawulekayo kwi-COVID-19 ekhoyo zokugonya esetyenziswayo ngoku. Ngelixa izitofu zokugonya ze-mRNA (zenziwe yiPfizer/BioNTech kunye neModerna) ziphethe umyalezo wokubonakaliswa kwe-antigen yentsholongwane egazini kwiiseli zomntu, esekwe kwi-adenovirus vector. zokugonya (ezinje nge-Oxford/AstraZeneca's ChAdOx1 nCoV-2019 kunye ne-Janssen's) zisebenzisa i-adenovirus eyenziwe ngokwemfuza njenge-vector ukuthwala i-spike-protein gene yenoveli ye-coronavirus ebonakaliswa kwiiseli zomntu ezisebenza njenge-antigen kuphuhliso olusebenzayo lokugomela. Ngaphaya koko, izitofu zokugonya ze-mRNA zineendleko kwaye zinemiba yonikezelo olubandayo ngelixa izitofu zokugonya ezisekwe kwi-adenovirus vector zichaphazeleka kwiziphumo ebezingalindelekanga ezinqabileyo zegazi legazi.  

*** 

Imithombo:  

1. I-WHO 2021. Iindaba - i-WHO idwelisa isitofu se-10 se-COVID-19 sosetyenziso olungxamisekileyo: Nuvaxovid. Iposwe nge-21 kaDisemba 2021, Iyafumaneka kwi-intanethi https://www.who.int/news/item/21-12-2021-who-lists-10th-covid-19-vaccine-for-emergency-use-nuvaxovid  
2. I-EMA 2021. Iindaba - i-EMA incoma i-Nuvaxovid ngokugunyaziswa kwi-EU, iThunyelwe 20/12/2021. Iyafumaneka kwi-intanethi https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu  
3. I-WHO 2021. Iindaba - i-WHO idwelisa isitofu se-9 se-COVID-19 kusetyenziso olungxamisekileyo ngenjongo yokwandisa ukufikelela kugonyo kumazwe anengeniso ephantsi. Ithunyelwe nge-17 kuDisemba 2021. Iyafumaneka kwi-intanethi https://www.who.int/news/item/17-12-2021-who-lists-9th-covid-19-vaccine-for-emergency-use-with-aim-to-increase-access-to-vaccination-in-lower-income-countries  
4. Tian, ​​JH., Patel, N., Haupt, R. et al. Umgqatswa wokugonya we-SARS-CoV-2 spike glycoprotein NVX-CoV2373 immunogenicity kwiimfene kunye nokhuseleko kwiimpuku. UNat Commun 12, 372 (2021). https://doi.org/10.1038/s41467-020-20653-8  
5. UKhan S., kunye noDhama K. 2021. Indima ye-Indiya kuzakuzo lwesitofu sogonyo lwe-COVID-19. Ijenali yeTravel Medicine, Volume 28, Issue 7, October 2021, taab064, Ipapashwe: 16 April 2021. DOI: https://doi.org/10.1093/jtm/taab064  
6. Soni R., 2021.Soberana 02 kunye no-Abdala: IiProtein zokuqala zeHlabathi ezidibanisa izitofu zokugonya ngokuchasene ne-COVID-19. Inzululwazi yaseYurophu. Ithunyelwe nge-30 Novemba 2021. Iyafumaneka kwi-intanethi https://www.scientificeuropean.co.uk/covid-19/soberana-02-and-abdala-worlds-first-protein-conjugate-vaccines-against-covid-19/  
7. I-Prasad U. 2021. Iintlobo zezitofu ze-COVID-19 eVogue: Ngaba Kunokubakho Into Engalunganga? Inzululwazi yaseYurophu. Ithunyelwe nge-20 kaJanuwari 2021. Iyafumaneka kwi-intanethi https://www.scientificeuropean.co.uk/covid-19/types-of-covid-19-vaccine-in-vogue-could-there-be-something-amiss/  
8. Soni R. 2021. Ikamva le-Adenovirus esekwe kwi-COVID-19 Izitofu (ezifana ne-Oxford AstraZeneca) ekukhanyeni okufunyaniswe kutshanje malunga nonobangela weziphumo ebezingalindelekanga ezinqabileyo zehlwili legazi. Inzululwazi yaseYurophu. Ithunyelwe nge-3 kaDisemba 2021. Iyafumaneka kwi-intanethi https://www.scientificeuropean.co.uk/covid-19/future-of-adenovirus-based-covid-19-vaccines-such-as-oxford-astrazeneca-in-light-of-recent-finding-about-cause-of-rare-side-effects-of-blood-clot/  

***